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Abstract: The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Conva-
lescent sera after infection with variants of concern (VOCs: B.1.1.7, n = 10; B.1.351, n = 1) and sera
from 100 vaccinees (Pfizer/BioNTech, BNT162b2, n = 33; Moderna, mRNA-1273, n = 11; AstraZeneca,
ChAdOx1 nCoV-19/AZD1222, n = 56) were tested for the presence of immunoglobulin G (IgG)
directed against the viral spike (S)-protein, its receptor-binding domain (RBD), the nucleoprotein (N)
and for virus-neutralizing antibodies (VNA). For the latter, surrogate assays (sVNT) and a Vero-cell
based neutralization test (cVNT) were used. Maturity of IgG was determined by measuring the
avidity in an immunoblot (IB). Past VOC infection resulted in a broad reactivity of anti-S IgG (100%),
anti-RBD IgG (100%), and anti-N IgG (91%), while latter were absent in 99% of vaccinees. Starting
approximately two weeks after the first vaccine dose, anti-S IgG (75–100%) and particularly anti-RBD
IgG (98–100%) were detectable. After the second dose, their titers increased and were higher than in
the convalescents. The sVNT showed evidence of VNA in 91% of convalescents and in 80–100%/100%
after first/second vaccine dose, respectively. After the second dose, an increase in VNA titer and
IgGs of high avidity were demonstrated by cVNT and IB, respectively. Re-vaccination contributes to
a more robust immune response.
Keywords: COVID-19; virus variants; vaccination; humoral immune response; IgG; titer;
virus-neutralizing antibodies; avidity
1. Introduction
The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1] is a great challenge for humanity. To date, 157,897,763 confirmed COVID-19 cases
have been reported to the World Health Organization (WHO), including 3,287,082 deaths [2].
Safe, effective, and widely available protective vaccines are essential to contain and end this
pandemic [3]. Almost all vaccines aim at the induction of neutralizing antibodies, which
are directed against the viral spike (S)-protein and in particular against its receptor-binding
domain (RBD) and which thereby prevent the infection of the cell [4]. Furthermore, all
vaccines should generate a robust cellular immune response [4,5].
So far, four vaccines have received conditional approval in the European Union [6].
These are, on the one hand, the messenger ribonucleic acid (mRNA) vaccines from
Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), in each of which the genetic
information for the complete SARS-CoV-2 S-protein has been optimized and liposomally
packaged to allow that a stable and highly immunogenic protein is expressed after vaccina-
tion [3,4]. On the other hand, there are two approved vector vaccines, which use either a
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replication-deficient rare human adenovirus 26 (Ad26. COV2; Janssen) or a chimpanzee
adenovirus (ChAdOx1 nCoV-19/AZD1222; AstraZeneca, in the following designated as
AZD1222) to introduce the genetic information of the S-protein into cells followed by the
expression of this SARS-CoV-2 surface protein [3,4]. Due to rare but serious side effects,
AZD1222 is no longer recommended unconditionally by the Standing Vaccination Com-
mission (STIKO) of the Robert Koch-Institute for individuals under 60 years of age living
in Germany. Vaccinations that have already started with AZD1222 should be continued
with an mRNA vaccine after 12 weeks [7].
Up to now, there have been only few studies in which the antibody response of
vaccinees to the newly developed mRNA and vector vaccines is examined with identical
tests. This makes it difficult to compare the studies.
Here, we investigated the anti-S- and anti-RBD immunoglobulin G (IgG) development
after the first vaccination with BNT162b2, mRNA-1273, or AZD1222 as well as after the
follow-up vaccination (data for BNT162b2 and mRNA-1273) including determination of
IgG avidity. We compared the results with the humoral immune response after infection
with SARS-CoV-2 variants of concern (VOCs). We also aimed to prove the development
and level of virus-neutralizing antibodies (VNA) with different methods in vaccinees and
convalescents. The IgG antibodies could be detected as early as two to three weeks after
the first vaccination, and in some cases VNA appeared already in this very early phase. In
particular after the second vaccination, an increase in the virus-neutralizing properties and
a maturation of the IgG antibodies were observed. These promising results underline the
high potential of all examined vaccines.
2. Materials and Methods
In this study, sera from eleven SARS-CoV-2 patients and from 100 vaccinees were
examined by SARS-CoV-2 specific antibody tests. In the case of the individuals who were
vaccinated with the vector vaccine, the sera were obtained shortly before or one week after
vaccination and then at weekly intervals for up to one month after vaccination. For those
who received the mRNA vaccines, the aim was to have their blood drawn immediately
before the second vaccination and then again 3–4 weeks after the second vaccination. All
subjects agreed to the serial blood samplings. Moreover, sera from eleven patients with a
recent infection caused by VOCs belonging to the SARS-CoV-2 PANGO [8] lineages B.1.1.7
(n = 10) and B.1.351 (n = 1) were examined. All infections were diagnosed by help of a
laboratory developed triplex RT-PCR as described previously [9]. The VOCs were found
in January 2021 by subsequent typing of RT-PCR positive samples using probe-based
melting curve assays (TIB Molbiol Syntheselabor GmbH, Berlin, Germany) followed by
next-generation full-genome sequencing in several cases. The convalescent sera were taken
28–41 days after RT-PCR based diagnosis. The ethics committee of the medical faculty of
the Christian-Albrechts-Universität zu Kiel (Kiel, Germany) approved the study design
(D467/20, 16 April 2020; amendment 2 February 2021).
2.1. SARS-CoV-2 S-Protein-Specific IgG Immunoassays
All sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (Institut
Virion\Serion GmbH, Würzburg, Germany) on a BEP 2000 Advance System (Siemens
Healthcare GmbH, Erlangen, Germany) following the manufacturers recommendations.
This enzyme-linked immunosorbent assay (ELISA) uses the whole SARS-CoV-2 S-protein as
antigen and was previously demonstrated by us to possess a high sensitivity of 96.2% for de-
tection of IgG after PCR-confirmed SARS-CoV-2 infection as well as an excellent specificity
of 100% [10]. Furthermore, all samples were tested in parallel with the Abbott SARS-CoV-2
IgG II Quant assay on the Alinity i system strictly following the manufacturer’s instructions
(both Abbott, Wiesbaden, Germany). This chemiluminescent microparticle immunoassay
detects IgG directed against the RBD of the S-protein. According to the manufacturer,
this assay has a sensitivity of 98.8% (sera taken ≥ 15 days after a positive SARS-CoV-2
PCR) and a specificity of 99.6%. Results of the anti-S IgG assay and of the anti-RBD IgG
Vaccines 2021, 9, 700 3 of 14
assay were given in Binding Antibody Units (BAU) per milliliter (BAU/mL) by applying
the conversion factors determined by the manufacturers based on the measurement of
the first WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (NIBSC-Code
20–136) [11]. For both anti-SARS-CoV-2 IgG tests, it was determined by us that borderline
results are to be assessed as positive.
2.2. SARS-CoV-2 IgG Immunoblots and Analysis of IgG Avidity
All sera obtained from SARS-CoV-2 patients and a serum obtained from each vaccine
recipients ≥ 21 days after vaccination, respectively, were tested with and without avidity
reagent in the recomLine SARS-CoV-2 IgG assay (Mikrogen GmbH, Neuried, Germany) fol-
lowing the manufacturer’s instructions. This immunoblot contains the recombinant nucleo
(N)-protein of the seasonal human coronaviruses HCoVs 229E, NL63, OC43, and HKU1
as well as the N-protein, the RBD and the entire S1 subunit of the SARS-CoV-2 S-protein,
which appear as separate antigens on a nitrocellulose-strip. The IgG avidity denotes the
strength of binding to the viral epitope and may correlate with seroprotection [12–14]. The
strength of binding was assessed separately for all three SARS-CoV-2 antigens and assigned
to the categories low (=1), intermediate (=2), and high (=3). Correspondingly, if several
antigens were detected, the mean value of the categorized IgG avidity was calculated.
The Dynablot Plus system was generally used and all blots were automatically evaluated
with a BLOTrix reader and the recomScan software (all from Mikrogen). The manufacturer
indicates an overall diagnostic sensitivity of 96.3% and a specificity of 98.8%. The high
diagnostic value of this test was also shown in our previous study [10].
2.3. Measurement of SARS-CoV-2-Neutralizing Antibodies
The SARS-CoV-2 convalescent sera and the vaccine recipient sera, which were already
characterized in the immunoblot, were also examined for their virus-neutralizing capacities.
For this, the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (Genescript USA,
Inc., Piscataway, NJ, USA) was applied as recommended by the supplier using the BEP
2000 system. This ELISA represents a surrogate virus neutralization test (sVNT, designated
here as sVNT #1). In the presence of RBD-specific antibodies, this part of the viral S-protein,
which has been conjugated to peroxidase, can no longer bind to the angiotensin-converting
enzyme 2 that is attached to the solid phase. After appropriate washing steps, the color
reaction turns out to be significantly weaker compared to RBD-antibody-free samples.
A signal inhibition ≥ 30% was valued as indicative for the presence of SARS-CoV-2-
neutralizing antibodies. Previously, sVNT #1 was found to have an overall sensitivity of
80.3% and a specificity of 99.2% [15] but may overestimate low-neutralizing antibodies [16].
For comparison, the TECO® SARS-CoV-2 Neutralization Antibody ELISA (TECOmedical
AG, Sissach, Switzerland) was used according to the manufacturer’s specifications on a
BEP 2000 system. This sVNT#2 works according to the same test principle as the cPassTM
assay, but uses a signal inhibition ≥ 20% as cut-off.
All convalescent sera and a selection of sera obtained from vaccinees were tested in a
laboratory-developed Vero cell-based neutralization assay (cVNT) under BSL-3 conditions
as previously reported [10]. However, for capacity reasons, we adapted this assay to a
96-well microtiter format. One day prior infection, 2.5 × 104 Vero cells (order no. 605372,
CLS Cell Lines Service GmbH, Eppelheim, Germany) were seeded per well. Then, sera
were heat-inactivated at 56 ◦C for 30 min and diluted from 1:10 to 1:1280 in cell culture
medium consisting of Dulbecco’s modified Eagle’s medium supplemented with 3.7 g/L
NaHCO3, 4.5 g/L glucose, 2 mM L-glutamine, and 1% (v/v) of Pen-Strep-Fungi mix
containing 10,000 U/mL penicillin, 10 mg/mL streptomycin, and 25 µg/mL amphotericin
B (all reagents from Bio&SELL GmbH, Feucht, Germany). Thereafter, 25 µL of each serum
dilution were mixed with 25 µL of virus suspension containing 50 plaque-forming units
of either an own ‘wildtype’ SARS-CoV-2 strain (isolated in spring 2020) or an own B.1.1.7
strain from January 2021. The mix was incubated for 1 h at 37 ◦C. Then, cells were
washed with phosphate-buffered saline (PBS, Bio&SELL), inoculated with 50 µL of the
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virus-serum dilutions, and incubated on a shaker for 1 h at room temperature, followed by
the addition of 50 µL of cell culture medium supplemented with 20% fetal calf serum (v/v).
After four days of incubation under standard conditions, cells were fixed with 4% (w/v)
paraformaldehyde in PBS and stained with an aqueous solution of 0.1% (w/v) crystal violet
and 20% (v/v) methanol. All dilution steps were tested in triplicates, and cytopathic effect
(CPE) formation was compared with an untreated cell control and a viral control. A serum
dilution > 1:10 that prevented CPE formation in at least two of three wells compared with
the viral control was considered reactive and likely protective. When an exact titer could
not be provided, a geometric mean of the two adjacent titers was calculated.
2.4. Data Evaluation and Statistical Calculations
Data were statistically analyzed using GraphPad Prism version 9.1.1 software (Graph-
Pad Software, San Diego, CA, USA). The Kruskal-Wallis test, a nonparametric, unpaired,
adjusted test, was used to analyze the development of IgGs with high avidity after infection
or vaccination and the emergence of VNA as determined by the two sVNTs. Changes
in antibody titers after the first and second vaccination and differences in neutralizing
capacity after infection with VOCs, both measured in the cVNT, were examined using the
Wilcoxon test, a paired nonparametric test. The dependence of the VNA measured in the
cVNT on avidity was analyzed using the Mann-Whitney test, an unpaired nonparametric
test, and the calculation of Cohen’s kappa. A significance level α of 0.05 was used for all
tests. p values of <0.05 to <0.0001 are indicated by one (*) to four (****) asterisks. The agree-
ment of the two sVNTs as well as the correlation between the sVNTs and the cVNT were
analyzed by calculating Cohen’s kappa and Spearman correlation coefficients, respectively.
3. Results
3.1. Composition of the Study Groups
This study includes eleven patients after SARS-CoV-2 VOC infection and 100 individ-
uals after vaccination with SARS-CoV-2 mRNA (n = 44) or vector (n = 56) vaccines. Four
individuals had their first serum sample drawn several days after the second vaccination
with BNT162b2. Therefore, a booster effect cannot be ruled out in these four individuals.
Accordingly, only the results of the second serum sample were taken into account in these
cases. Weekly follow-up samples were available from six individuals in the BNT162b2
group and from almost everyone who received the vector vaccine. Due to the different
vaccination schemes [7], we were able to examine the sera of the participants who were vac-
cinated with the mRNA vaccines also after the second homologous vaccination. However,
no second serum was available in one participant from the BNT162b2 group. The individu-
als who received the vector vaccine are currently waiting for their second (heterologous)
vaccination or have recently received it. Therefore we cannot yet make any statements
about the development of humoral immunity in this subgroup. The composition of the
study groups is listed in detail in Table 1.
3.2. Anti-S- and Anti-RBD-Specific IgG Response after SARS-CoV-2 Infection and Vaccination
Anti-S- and anti-RBD IgG antibodies could be detected in the convalescent sera of all
eleven SARS-CoV-2 VOC patients. The mean anti-S IgG titer was 355 BAU/mL and the
mean anti-RBD IgG titer was determined with 506 BAU/mL. All individuals who received
their first mRNA vaccination had anti-S IgG and anti-RBD IgG, with a mean titer of 147
to 357 BAU/mL and 217 to 706 BAU/mL, respectively. In individuals, who received the
vector vaccine, prevalence of anti-S IgG was 75% (mean titer 66 BAU/mL) and of anti-RBD
IgG was 98% (mean titer 91 BAU/mL). After the second vaccination, an increase in mean
titers of anti-S IgG (BNT162b2: 813 BAU/mL, mRNA-1273: 1305 BAU/mL) and anti-RBD
IgG (BNT162b2: 2057 BAU/mL, mRNA-1273: 3472 BAU/mL) was evident (Figure 1).
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Table 1. Composition of the study groups.
Groups Number ofIndividuals
Median Age
in Years
Age Span in
Years
Gender
(Female/Male)
Time Span from RT-PCR or the
First/Second Vaccination to Serum
Sampling in Days
SARS-CoV-2 VOC infection 11 52 18 to 69 6/5 28 to 41
SARS-CoV-2 vaccination 100 41 18 to 62 77/23 −13 to 65/15 to 49
mRNA vaccines
Pfizer/BioNTech (BNT162b2) 33 45 23 to 62 25/8 0 to 37/15 to 49
Moderna (mRNA-1273) 11 48 33 to 61 7/4 22 to 34/20 to 22
vector vaccine
AstraZeneca
(ChAdOx1 nCoV-19/AZD1222) 56 31 18 to 60 45/11
−13 to 65/
no data available yet
mRNA: messenger ribonucleic acid; RT-PCR: one-step reverse transcription real-time polymerase chain reaction for detection of SARS-CoV-2;
VOC: variant of concern.
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3.3. Kinetics of Anti-S- and Anti-RBD IgG after First SARS-CoV-2 Vaccination
At least two blood samples drawn at short time intervals were available for 40 individ-
uals vaccinated with the vector vaccine AZD1222 and for six individuals vaccinated with
BNT162b. The kinetics of anti-S and anti-RBD IgGs were measured accordingly. The first
antibodies were already detectable approximately ten days after the immunization. The
seronegativity of sera taken shortly before or at the time of vaccination can be interpreted
as an indication of the high specificity of both antibody tests. In addition, there is a high
probability that those who have been vaccinated were immunologically naïve and had no
previous SARS-CoV-2 infection (Figure 2).
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3.4. Differences in the Anti-N IgG Response between SARS-CoV-2 Infected and Vaccinated
Individuals and Development of High Avidity SARS-CoV-2 IgGs after the Second Vaccination
In the recomLine immunoassay, anti-N IgG was demonstrated in almost all convales-
cent sera (91%, 10/11), and anti-RBD as well as anti-S1 IgG was found in 82% (9/11). In
the vaccinees, seroreactivity pattern was restricted to anti-S1- and anti-RBD IgG; only one
vaccine recipient presented anti-N IgG (Table 2).
Table 2. Pattern of Immunoglobulin G (IgG) reactivity and avidity in patients after infection with SARS-CoV-2 variants of
concern (VOCs) or after first (1) and second (2) immunization with messenger ribonucleic acid (BNT162b2; mRNA-1273) or
vector (AZD1222) vaccines.
Groups Anti-NIgG
Anti-RBD
IgG
Anti-S1
IgG
High IgG Avidity
(Index ≥ 2.5)
n n % n % n % n %
VOCs 11 10 90.9 9 81.8 9 81.8 4 36.4
BNT162b2 (1) 27 0 0 23 85.2 26 96.3 2 7.4
BNT162b2 (2) 21 0 0 21 100 21 100 20 95.2
m-1273 (1) 11 0 0 11 100 11 100 2 18.2
m-1273 (2) 10 0 0 10 100 10 100 9 90
AZD1222 (1) 56 1 1.8 50 89.3 54 96.4 3 5.4
Results were obtained with the recomLine immunoassay. Please note, that the number in the groups differs from the number of the
individuals included in the study: If a high IgG avidity was observed after a single vaccination, the serum was not examined again after the
second vaccination. Likewise, sera from several individuals were only available after the first/second vaccination. N: nucleoprotein. RBD:
receptor-binding domain of the spike (S)-protein. S1: S1 subunit of the S-protein.
The development of SARS-CoV-2 IgG avidity was studied with the recomLine assay.
Almost all sera taken ≥21 days after the first vaccination showed only low to intermediate
IgG avidities (mean indices 1.2 to 1.5; Table 2 and Figure 3). In contrast, IgG of high
avidity were found in the sera taken after the second vaccination (mean indices 2.8 to 2.9;
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Table 2 and Figure 3). Their mean avidity indices were significantly higher than after first
vaccination and after infection with VOCs (mean index 1.6; Table 2 and Figure 3).
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3.5. Appearance of Potent Virus-Neutralizing Antibodies after the Second Vaccination
Surrogate tests should be able to predict the virus-neutralizing properties of a serum.
They measure the antibody-mediated prevention of the binding of the viral RBD to the
cellular receptor ACE2. The sera of all infected and all vaccinees were examined in the
sVNT#1. In this test, almost all VOC patients (n = 10; 91%) and all vaccinees after first
vaccination with an mRNA vaccine showed relevant inhibition of ACE2 binding (≥30%).
An initial vaccination with AZD1222 was associated with presence of inhibiting
antibodies in 80% of these individuals. For the separate study groups, the mean percentage
of the inhibition of binding varies between 50.8% to 96.5% in this sVNT. Sixty-eight sera
were also tested with sVNT#2. In this assay, the mean percentage of the inhibition varied
from 16 to 99.5% (Figure 4a). The qualitative agreement of both assays was classified as
‘fair’ (Table 3; unweighted Kappa = 0.33), but we found a ‘strong’ correlation of inhibition
values in % (Figure 4b; Spearman correlation coefficient = 0.89).
The eleven convalescent sera were tested for presence of VNA against ‘wildtype’
SARS-CoV-2 and B.1.1.7 in the cVNT. In addition, sera obtained ≥ 21 days after vaccination
were included. Since only eleven vaccinees were vaccinated with mRNA-1273, eleven indi-
viduals were selected from the other two vaccination groups who roughly corresponded in
age and gender to the recipients of mRNA-1273 (Figure 5). Data from additional individual
sera that were examined in the cVNT were included in the following test comparisons.
Among other things, the results of the cVNT were compared with the results of both sVNTs.
This showed that the sVNTs overestimate the neutralizing properties of the sera. Raising
the sVNTs cut-off could reduce this overestimation (Figure 6). There was a moderate
agreement of qualitative cVNT results and of anti-SARS-CoV-2 IgG avidity categories
(‘wildtype’: unweighted Kappa = 0.60; B.1.1.7: unweighted Kappa = 0.58; Table 4). The
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positive and negative predictive values, which suggest the presence of VNA from a high
IgG avidity, were calculated on the basis of the data given in Table 4. They reach 100%
and 70%, respectively, regardless of the viral antigen used in the cVNT. In line with this,
VNA titer were significantly higher in individuals with highly avid anti-SARS-CoV-2 IgG
(Figure 7).
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Table 3. Qualitative agreement of results obtained with both surrogate virus neutralization tests (sVNT). 
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No evidence for VNA 4 1 5 7.4 
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VNA: virus-neutralizing antibodies. 
Figure 4. (a) Investigation of convalescent sera (after infection with SARS-CoV-2 variants of concern,
VOCs) and of vaccinees sera in two surrogate virus neutralization tests (sVNT #1 and #2). These
assays measure the antibody-mediated prevention of the binding of the viral receptor-binding
domain to the angiotensin-converting enzyme 2. The degree of binding inhibition is given as a
percentage and is taken as an indication of the presence of virus-neutralizing antibodies. The mean
and the 95% confidence interval are given for each group of patients (VOCs: B.1.1.7 filled green
dots; B.1.351 empty green dot) or vaccinees after first (1) or second (2) vaccination with messenger
ribo ucleic acid (BNT162b2; mRNA-1273) or v ctor vaccines (AZD1222), respectivel . Horizontal
dotted lines in icate the cut-offs of both assays. Data were valued for statistical significance by a
non-parametric, unpaired, and adjusted test (Kruskal-Wallis test). Ns: not significant; *: p < 0.05;
**: p < 0.01; ***: p < 0.001; ****: p < 0.0001. (b) Quantitative agreement between both sVNTs. The
Spearman correlation coefficient was calculated with 0.89.
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Table 3. Qualitative agreement of results obtained with both surrogate virus neutralization tests (sVNT).
sVNT#2 (Decision Limit ≥ 20%)
No evidence for VNA Evidence for VNA n %
sVNT#1
(decision limit ≥ 30%)
No evidence for VNA 4 1 5 7.4
Evidence for VNA 11 52 63 92.6
n 15 53 68
% 22.1 77.9
VNA: virus-neutralizing antibodies.
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green dot; n = , B.1.351, empty green dot) or after fir t (1) and second (2) vaccination with with
messenger ribonucleic (BNT162b ; mRNA-1273) and vector (AZD1222) vaccines (n = 11 a e and
gender m tched vaccinees p r vaccine group). Results were obtained in a laborat ry-develop d
Vero-cell based neutralization assay (cVNT) under BSL-3 conditions. A serum dilution of >1:10 is
considered as protective. The reciprocal geometric mean titer and the 95% confidence intervals are
given. Stars indicate statistical significance (***: p < 0.001) calculated in a paired, non-parametric test
(Wilcoxon test).
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Figure 6. Comparison of the results of the surrogate neutralization tests (sVNT) #1 (a) and #2 (b)
with those of the cell-based neutralization test (cVNT) using a ‘wildtype’ SARS-CoV-2 strain (wt)
and a B.1.1.7 strain as antigens. A serum dilution of >1:10 is considered as protective. The decision
limits for relevant inhibition of SARS-CoV-2 receptor-binding domain interaction with the human
angiotensin-converting enzyme 2 varies between ≥20% (sVNT#2) and ≥30% (sVNT#1). Spearman
correlation coefficients were calculated with 0.85 (sVNT#1 vs. cVNT with wt), 0.80 (sVNT#1 vs. cVNT
with B.1.1.7), 0.92 (sVNT#2 vs. cVNT with wt), and 0.85 (sVNT#2 vs. cVNT with B.1.1.7), respectively.
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Table 4. Qualitative agreement of results obtained in the cell-based virus neutralization test and of IgG avidities measured
in the recomLine assay.
IgG Avidity
n %
Low/Intermediate High
cVNT (wt)
No evidence for VNA 37 0 37 47.4
Evidence for VNA 16 25 41 52.6
n 53 25 78
% 67.9 32.1
cVNT (B.1.1.7)
No evidence for VNA 36 0 36 46.2
Evidence for VNA 17 25 42 53.8
n 53 25 78
% 67.9 32.1
The cell-based virus neutralization test (cVNT) was conducted with a SARS-CoV-2 ‘wildtype’ (wt) strain and with a member of the B.1.1.7
lineage as separate antigens. A titer > 1:10 was taken as evidence for presence of virus neutralizing antibodies (VNA).
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4. Discussion
In this study, the humoral immune response after SARS-CoV-2 infection or vaccination
was examined. The convalescent sera were obtained from eleven patients after a SARS-CoV-
2 infection caused by two VOCs. Even if the identification of the underlying virus lines by
sequencing was not carried out in every case, the key mutations detected by RT-PCR and
subsequent melting curve analysis indicate that these viruses belong to the SARS-CoV-2
VOC lines B.1.1.7 (n = 10) and B.1.351 (n = 1). The S-protein of variant B.1.1.7 has seven
amino acid (aa) changes, and further three aa have been deleted [17]. The aa change N501Y
of the RBD, which is also found in VOC B.1.351, is associated with increased binding to the
cellular receptor ACE2 [17]. The S-protein of the B.1.351 variant has seven aa changes, three
of them in the RBD, as well as a deletion of three adjacent aa [17]. In this respect, it can be
assumed that, in addition to impairing the virus-neutralizing activity of vaccine sera [17],
the reliable detection of antibodies in VOC convalescents by S- and RBD-specific tests could
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also be problematic. In the present study, anti-S- and RBD-specific IgG antibodies were
found in all convalescents, the mean titer of which were even higher than after a primary
vaccination with BNT162b2 and AZD1222. The results suggest that these assays can reliably
monitor humoral immune response after a B.1.1.7 or B.1.351 infection. In almost all cases
the vaccination led to the development of IgG against the RBD. However, about 25% of
individuals vaccinated with AZD1222 tested negative in the anti-S IgG test. The anti-SARS-
CoV-2 specific IgG antibodies were already detectable approximately two weeks after
administration of the first vaccination. Thus, the generally high level of seroreactivity and
its rapid development indicate a high immunogenicity of the three vaccines. Our results
are consistent with a recent publication on IgG responses to various S-protein subunits
three weeks after single dose vaccination with the mRNA vaccine BNT162b2 [18]. The
slightly lower IgG titers seen from day 21 after the first administration of the vector vaccine
in comparison to the mRNA vaccines were also reported in a recent preprint [19,20]. More
important than the observed high seroreactivity is the substantial reduction in SARS-CoV-2
infections and infection-related hospital admissions previously reported after a single
vaccination with BNT162b2 or AZD1222 [19,21–23].
The IgG response of convalescent and vaccinated individuals differs markedly, since
post infection, in addition to the anti-S/-RBD IgG antibodies, anti-N IgG can also be
detected. This difference is not surprising, but an effect of the vaccination, which solely
leads to the expression of the S-protein, against which specific antibodies are then formed.
The peculiarity can be used for diagnostic purposes, for example to verify the suspicion of
a previous infection or a vaccination breakthrough.
A few weeks after the booster vaccination, the mean IgG titer were not only higher but
there was also a marked increase in mean IgG avidity. In contrast, the mean IgG avidities
after first vaccination or infection were only low to intermediate. In our previous study, less
than 30% of outpatients developed highly avid IgG antibodies several weeks to months after
SARS-CoV-2 infection [10]. A high IgG avidity results from a natural maturation process
that takes some time and is an indicator of the strength of the interaction between the
antibody and its epitope [12–14,24]. Due to the short interval between the first vaccination
and the booster which is recommended for mRNA vaccines [7], it cannot be ruled out that
one dose alone is sufficient for the formation of highly avid IgG after several weeks and
prior booster vaccination speeds up the process. Regardless of the causative mechanism,
we consider the detection of highly avid anti-S1/-RBD IgG to be a very encouraging sign
and an expression of the development of a more robust humoral immunity.
The sera from almost all convalescents and 80 to 100% of the sera from those who
were first vaccinated showed an inhibition of RBD-binding to ACE2 of at least 30% in
the sVNT#1. These individuals are believed to possess virus-neutralizing antibodies.
However, the percentage of inhibition varied. The lowest values were found after a single
vaccination with the vector vaccine, the highest values after the second vaccination with the
mRNA vaccines. The qualitative agreement and quantitative correlation of the inhibitions
measured in both sVNTs was ‘fair’ and ‘strong’, respectively.
In the cVNT, VNA against a canonical non-B.1.1.7 strain (designated here as ‘wildtype’)
and against a member of the B.1.1.7 lineage were found in 64% and 91% of the convalescent
sera. In this group, the mean neutralizing titer against B.1.1.7 was significantly higher
than the mean neutralizing titer against the ‘wildtype’ strain. This can be interpreted as
a serological indication of the previous infection with B.1.1.7, which was diagnosed in
almost all patients. Such an effect could not be observed for the three groups of vaccinees
(statistical data not shown). After the first vaccination, a broader occurrence of VNA
against ‘wildtype’ virus and B.1.1.7 was detectable only in one group of mRNA vaccinees,
whereas the second vaccination resulted in a significant increase of VNA in cVNT, as also
reported by others [3]. A lower in-vitro vaccine-induced virus-neutralizing activity against
the B.1.1.7 variant was previously demonstrated for AZD1222 vaccinees while the clinical
vaccine efficacy was similar against a ‘wildtype’ strain and the B.1.1.7 variant [25]. In the
present study, VNA against the ‘wildtype’ virus and against B.1.1.7 increased to similarly
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high levels after second vaccination. Our laboratory-developed cVNT [10] is based on the
visual assessment of the prevention of the virus-induced CPE by the serum dilution. Thus,
this assay evaluates less the reduction in the number of plaques but rather their general
prevention and is therefore to be assessed as very conservative. This could explain the
poor correlation of lower titers with the sVNT. Data on the diagnostic performance of the
sVNTs for detection of low neutralizing sera are inconsistent: both underestimates and
overestimates have been reported [15,16,26]. Our results support the observation that the
sVNTs overestimate low neutralizing sera. Thus, it might be useful to increase their cut-off
values, perhaps even higher than the 50% previously suggested for sVNT#1 [16]. From our
point of view, this increase in the sVNT cut-offs would improve their diagnostic accuracy.
Then these assays could show their advantages over the cVNT, which consist in the fact that
they can be automated, standardized and carried out under routine laboratory conditions.
We found a moderate qualitative agreement between the results of cVNT and the
determination of anti-SARS-CoV-2 IgG avidity. Interestingly, individuals with a high VNA
had also anti-SARS-CoV-2 IgG of high avidity. Both high-quality antibody properties were
detectable after the booster vaccination. It can therefore be assumed that the detection of
highly avid anti-SARS-CoV-2 IgG is a good predictor for the presence of virus neutralization
capacities in the serum. However, statements on the approximate VNA titer level cannot be
derived from the avidity. The association between the presence of highly avid anti-SARS-
CoV-2 IgG and VNA should be verified in further, more extensive studies.
A recent investigation from Israel shows that after a complete vaccination with two
BNT162b2 doses, the rate of asymptomatic infections is reduced by more than 90% and
of symptomatic infections including hospital admissions and deaths by more than 95%.
This is particularly noteworthy since almost all infections in Israel are now caused by
VOC B.1.1.7 [27]. A more than 95% effectiveness of the BNT162b2 vaccination against
severe, critical, or fatal infection with VOCs B.1.1.7 and B.1.351 has been also reported from
Qatar [28].
In summary, the results of our study show that the administration of a single vaccine
dose already leads to a high rate of anti-S-/-RBD-specific IgG antibodies and therefore a
certain protection against (severe) infections can be assumed. However, in order to achieve
a more robust immunity, a second vaccination is required.
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